

**MARKED UP VERSION OF THE CLAIMS**

1-34. (Cancelled)

35. (Currently Amended) A bioerodible implant for treating an inflammation-mediated condition of an eye in an individual, the implant comprising a steroidal anti-inflammatory agent and a bioerodible copolymer without an added release modifier, the implant structured to be placed in the vitreous of the eye by being an extruded filament with a weight between about 500  $\mu$ g and about 1100  $\mu$ g which and releases delivers at least about 20% of the agent into the vitreous within about 20 days in vitro~~after the implant has been placed in the vitreous of the eye in an amount sufficient to reach an in vivo concentration equivalent to at least about 0.05  $\mu$ g/ml dexamethasone within about 48 hours and to maintain an in vivo concentration equivalent to at least about 0.03  $\mu$ g/ml dexamethasone for at least about three weeks.~~

36. (Cancelled).

37. (Previously presented) The implant according to claim 35, wherein the steroidal anti-inflammatory agent is selected from the group consisting of cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone and mixtures thereof.

38. (Previously presented) The implant according to claim 35, wherein the steroidal anti-inflammatory agent is dexamethasone.

39. (Currently Amended) The implant according to claim 35, ~~which wherein the implant releases at least about 30% of is structured to deliver the agent after about 20 days in vivoto the vitreous in an amount sufficient to reach an in vivo concentration equivalent to at least about 0.1 µg/ml dexamethasone within about 48 hours and to maintain an in vivo concentration equivalent to at least about 0.03 µg/ml dexamethasone for at least about three weeks.~~

40-41. (Cancelled).

42. (Previously presented) The implant according to claim 35, wherein the steroidal anti-inflammatory agent comprises about 50 to about 80 weight percent of the implant.

43. (Previously presented) The implant according to claim 42, wherein the steroidal anti-inflammatory agent comprises about 70% by weight of the implant.

44. (Previously presented) The implant according to claim 35, wherein the bioerodible copolymer is a polyester.

45. (Previously presented) The implant according to claim 44, wherein the bioerodible copolymer is polylactic acid polyglycolic acid (PLGA) copolymer.

46. (Previously presented) The implant according to claim 35, wherein the inflammation mediated condition of the eye to be treated is selected from the group consisting of uveitis, macular edema, macular degeneration, retinal detachment, ocular tumors, fungal infections, viral

infections, multifocal choroiditis, diabetic uveitis, proliferative vitreoretinopathy (PVR), sympathetic ophthalmia, Vogt Koyanagi-Harada (VKH) syndrome, histoplasmosis, and uveal diffusion.

47. (Previously presented) The method according to claim 46, wherein the inflammation mediated condition of the eye to be treated is uveitis.

48-50 (Cancelled).

51. (Previously presented) The implant according to claim 35, wherein the individual whose eye is to be treated is a human.

52. (Currently Amended) An implant for treating an inflammation-mediated condition of the eye in an individual, comprising a solid body structured for placement into the vitreous of the eye by being an extruded filament with a weight between about 500  $\mu$ g and about 1100  $\mu$ g which releases at least about 30% of the agent within about 20 days in vitro~~after, said body comprising particles of a steroidal anti-inflammatory agent entrapped within a biodegradable polymer without an added release modifier, whereby said agent is released from the body by erosion of the polymer, and whereby said agent is delivered to the vitreous at a rate and for a time sufficient to reach an in vivo concentration equivalent to at least about 0.05  $\mu$ g/ml dexamethasone within about 48 hours, and to maintain an in vivo concentration equivalent to at least about 0.03  $\mu$ g/ml dexamethasone for at least about three weeks.~~

53-54. (Cancelled)

55. (Currently Amended) The implant according to claim 52<sub>3</sub>, wherein the steroidal anti-inflammatory agent is selected from the group consisting of cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone and mixtures thereof.

56. (Currently Amended) The implant according to claim 53<sub>2</sub>, wherein the steroidal anti-inflammatory agent is dexamethasone.

57-60. (Cancelled)

61. (Currently Amended) The implant according to claim 52<sub>3</sub>, wherein the steroidal anti-inflammatory agent comprises about 50 to about 80 weight percent of the implant.

62. (Previously presented) The implant according to claim 61, wherein the steroidal anti-inflammatory agent comprises about 70% by weight of the implant.

63. (Previously presented) The implant according to claim 61, wherein the steroidal anti-inflammatory agent comprises about 50% by weight of the implant.

64. (Currently Amended) The implant according to claim 52<sub>3</sub>, wherein the bioerodible copolymer is a polyester.

65. (Currently Amended) The implant of claim 523, wherein the bioerodible copolymer is polylactic acid polyglycolic acid (PLGA) copolymer.

66. (Currently Amended) The implant according to claim 523, wherein the inflammatory mediated condition of the eye to be treated is selected from the group consisting of uveitis, macular edema, macular degeneration, retinal detachment, ocular tumors, fungal infections, viral infections, multifocal choroiditis, diabetic uveitis, proliferative vitreoretinopathy (PVR), sympathetic ophthalmia, Vogt Koyanagi-Harada (VKH) syndrome, histoplasmosis, and uveal diffusion.

67. (Previously presented) The implant according to claim 66, wherein the inflammation-mediated condition of the eye to be treated is uveitis.

68-81 (Cancelled).